Skip to content
Oncology Research Hub

Nebraska

Cancer clinical trials in Nebraska

177 cancer studies are recruiting participants at sites in 10 cities across Nebraska as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Every Nebraska city with a recruiting study

By research area: Lung Cancer (51), Breast Cancer (37), Lymphoma (33), Prostate Cancer (32), Pancreatic Cancer (15), Melanoma (9).

Omaha (152), Lincoln (30), Bellevue (20), Grand Island (18), Kearney (18), Hastings (3), North Platte (2), Papillion (2), Fremont (1), Norfolk (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Nebraska

Basic details from each study's public record (the 12 most recently updated of 177). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Grand Island · Omaha
    Registry record
    NCT07748208 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Nebraska on ClinicalTrials.gov.

Lung cancer: recently updated in Nebraska

  1. A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    IDEAYA Biosciences
    Recruiting in
    Omaha
    Registry record
    NCT07277413 · updated
  2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Lincoln
    Registry record
    NCT07513376 · updated
  3. A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Recruiting in
    Omaha
    Registry record
    NCT03460977 · updated
  4. A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Recruiting in
    Omaha
    Registry record
    NCT07063745 · updated
  5. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bellevue · Kearney · Lincoln · and 1 more U.S. location
    Registry record
    NCT04267848 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Nebraska on ClinicalTrials.gov.

Prostate cancer: recently updated in Nebraska

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Kearney · Omaha
    Registry record
    NCT04423211 · updated
  2. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Omaha
    Registry record
    NCT06136624 · updated
  3. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Bellevue · Omaha
    Registry record
    NCT03866382 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Nebraska on ClinicalTrials.gov.

Melanoma: recently updated in Nebraska

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Grand Island · Kearney · Omaha
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Nebraska on ClinicalTrials.gov.

Lymphoma: recently updated in Nebraska

  1. Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Recruiting in
    Omaha
    Registry record
    NCT06806033 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Lincoln · Omaha
    Registry record
    NCT06890884 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Nebraska on ClinicalTrials.gov.

Ask about studies in Nebraska

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call